{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:13Z","timestamp":1792184653520,"version":"4.4.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>The incidence and nature of discontinuation symptoms following antidepressant cessation remain unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the presence of discontinuation symptoms using standardized scales (eg, Discontinuation-Emergent Signs and Symptoms [DESS]) and the incidence of individual discontinuation symptoms in individuals who stop taking antidepressants.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>The databases Embase, PsycINFO, Ovid MEDLINE, and Cochrane Library were systematically searched from inception until November 7, 2023.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Randomized clinical trials (RCTs) reporting discontinuation symptoms using a standardized scale or individual symptoms (eg, adverse events) following antidepressant cessation were included.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Data extracted were cross-checked by 2 reviewers. Additional unpublished data from 11 RCTs were included. A random-effects meta-analysis was conducted to calculate standardized mean difference between individuals who discontinued an antidepressant vs those who continued an antidepressant or discontinued placebo. A proportion and odds ratio (OR) meta-analysis was performed to assess incidence of individual discontinuation symptoms compared to placebo. Subgroup analyses were conducted to compare different antidepressants. Data analysis was conducted between September 2024 and December 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were incidence and nature of antidepressant discontinuation symptoms measured using standardized or unstandardized scales.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 50 studies were included, 49 of which were included in meta-analyses. The 50 studies included 17\u202f828 participants in total, with 66.9% female participants and mean participant age of 44 years. Follow-up was between 1 day and 52 weeks. The DESS meta-analysis indicated increased discontinuation symptoms at 1 week in participants stopping antidepressants (standardized mean difference, 0.31; 95% CI, 0.23-0.39; number of studies [k]\u2009=\u200911; n\u2009=\u20093915 participants) compared to those taking placebo or continuing antidepressants. The effect size was equivalent to 1 more symptom on the DESS. Discontinuation of antidepressants was associated with increased odds of dizziness (OR, 5.52; 95% CI, 3.81-8.01), nausea (OR, 3.16; 95% CI, 2.01-4.96), vertigo (OR, 6.40; 95% CI, 1.20-34.19), and nervousness (OR, 3.15; 95% CI, 1.29-7.64) compared to placebo discontinuation. Dizziness was the most prevalent discontinuation symptom (risk difference, 6.24%). Discontinuation was not associated with depression symptoms, despite being measured in people with major depressive disorder (k\u2009=\u20095).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This systematic review and meta-analysis indicated that the mean number of discontinuation symptoms at week 1 after stopping antidepressants was below the threshold for clinically significant discontinuation syndrome. Mood worsening was not associated with discontinuation; therefore, later presentation of depression after discontinuation is indicative of depression relapse.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.1362","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:00:48Z","timestamp":1752073248000},"page":"896","source":"Crossref","is-referenced-by-count":43,"title":["Incidence and Nature of Antidepressant Discontinuation Symptoms"],"prefix":"10.1001","volume":"82","author":[{"given":"Michail","family":"Kalfas","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimosthenis","family":"Tsapekos","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Butler","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Health NHS Foundation Trust, Oxford, United Kingdom"},{"name":"Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Pillinger","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Strawbridge","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree Bhaskar","family":"Bhat","sequence":"additional","affiliation":[{"name":"Cambridge and Peterborough NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Deakin University, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Cowen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan W.","family":"Joyce","sequence":"additional","affiliation":[{"name":"Institute of Population Health, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine M.","family":"Pariante","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"},{"name":"Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Hayes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Jauhar","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"},{"name":"Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi250035r1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/070674375900400111","article-title":"Clinical experience with imipramine (G22355) in the treatment of depression.","volume":"4","author":"Mann","year":"1959","journal-title":"Can Psychiatr Assoc J"},{"key":"yoi250035r2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211067656","article-title":"Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review.","volume":"12","author":"S\u00f8rensen","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"issue":"8","key":"yoi250035r3","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41380-024-02445-4","article-title":"Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.","volume":"29","author":"Vinkers","year":"2024","journal-title":"Mol Psychiatry"},{"key":"yoi250035r5","first-page":"9","article-title":"American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder.","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"7","key":"yoi250035r6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"yoi250035r7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2215-0366(24)00274-8","article-title":"Incidence of antidepressant withdrawal symptoms.","volume":"11","author":"Bisol","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"yoi250035r8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"5","key":"yoi250035r9","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41380-024-02782-4","article-title":"Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.","volume":"30","author":"Zhang","year":"2025","journal-title":"Mol Psychiatry"},{"key":"yoi250035r10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"yoi250035r11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"2","key":"yoi250035r14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/jwh.2011.2764","article-title":"The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.","volume":"21","author":"Gallagher","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"yoi250035r15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/JCP.0b013e31817efbac","article-title":"Physician Withdrawal Checklist (PWC-20).","volume":"28","author":"Rickels","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"yoi250035r16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1192\/bjp.176.4.363","article-title":"Interruption of selective serotonin reuptake inhibitor treatment. double-blind, placebo-controlled trial.","volume":"176","author":"Michelson","year":"2000","journal-title":"Br J Psychiatry"},{"issue":"14","key":"yoi250035r17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2106356","article-title":"Maintenance or discontinuation of antidepressants in primary care.","volume":"385","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"yoi250035r18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/13651501.2017.1301488","article-title":"Silexan does not cause withdrawal symptoms even when abruptly discontinued.","volume":"21","author":"Gastpar","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"10","key":"yoi250035r19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1001\/jamapsychiatry.2015.1472","article-title":"Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial.","volume":"72","author":"Yonkers","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi250035r20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JCP.0000000000000100","article-title":"Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg\/d.","volume":"34","author":"Khan","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"yoi250035r22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.","volume":"19","author":"Montgomery","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"yoi250035r23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.","volume":"28","author":"Stein","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"yoi250035r24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.","volume":"73","author":"Stein","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi250035r25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YIC.0b013e32830cebed","article-title":"Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg\/day for major depressive disorder in a placebo-controlled trial.","volume":"23","author":"Boyer","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"yoi250035r26","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1185\/03007990802161923","article-title":"Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/day and 100 mg\/day in outpatients with major depressive disorder.","volume":"24","author":"Liebowitz","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"yoi250035r27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JCP.0b013e3181c94c4d","article-title":"Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.","volume":"30","author":"Rickels","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"Pt 1","key":"yoi250035r28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.","volume":"31","author":"Tourian","year":"2009","journal-title":"Clin Ther"},{"issue":"3","key":"yoi250035r29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"yoi250035r30","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"yoi250035r31","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","article-title":"A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.","volume":"66","author":"Montgomery","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi250035r32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"yoi250035r33","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1176\/ajp.154.12.1760","article-title":"Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.","volume":"154","author":"Fava","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi250035r34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1192\/bja.2021.62","article-title":"Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies.","volume":"28","author":"Horowitz","year":"2022","journal-title":"BJPsych Adv"},{"issue":"2","key":"yoi250035r35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","article-title":"Estimating risk of antidepressant withdrawal from a review of published data.","volume":"37","author":"Horowitz","year":"2023","journal-title":"CNS Drugs"},{"issue":"20","key":"yoi250035r36","first-page":"355","article-title":"Antidepressant withdrawal and rebound phenomena.","volume":"116","author":"Henssler","year":"2019","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"yoi250035r37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S2215-0366(19)30183-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms.","volume":"6","author":"Selvaraj","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"yoi250035r38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S2215-0366(19)30182-8","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms.","volume":"6","author":"Ruhe","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"yoi250035r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115926","article-title":"Association between duration of antidepressant treatment for major depressive disorder and relapse rate after discontinuation: a meta-analysis.","volume":"337","author":"Hu","year":"2024","journal-title":"Psychiatry Res"},{"issue":"9","key":"yoi250035r40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3109\/00016481003602082","article-title":"A possible explanation for dizziness following SSRI discontinuation.","volume":"130","author":"Smith","year":"2010","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"yoi250035r41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32872\/cpe.v1i1.29642","article-title":"Evidence of a media-induced nocebo response following a nationwide antidepressant drug switch.","volume":"1","author":"MacKrill","year":"2019","journal-title":"Clin Psychol Eur"},{"issue":"5","key":"yoi250035r42","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon.","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"yoi250035r43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and nocebo effects.","volume":"382","author":"Colloca","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"yoi250035r44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review.","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother Psychosom"},{"issue":"3","key":"yoi250035r45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/acps.13334","article-title":"Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.","volume":"144","author":"Lambrichts","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"yoi250035r13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2019"},{"key":"yoi250035r4","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management. Accessed March 13, 2025. https:\/\/www.nice.org.uk\/guidance\/ng222"},{"key":"yoi250035r12","unstructured":"Stata 18. Version 18. StataCorp; 2023. Accessed December 20, 2024. http:\/\/www.stata.com\/"},{"key":"yoi250035r21","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, , eds. Cochrane Handbook for Systematic Reviews of Interventions. Accessed March 13, 2025. http:\/\/www.training.cochrane.org\/handbook"},{"key":"yoi250035r46","unstructured":"Quality statement 4: stopping antidepressants. National Institute for Health and Care Excellence (NICE). https:\/\/www.nice.org.uk\/guidance\/qs8\/chapter\/Quality-statement-4-Stopping-antidepressants"},{"key":"yoi250035r47","unstructured":"Skerrett? K. Thomas Kingston: prevention of future deaths report. Gloucestershire Coroner's Court. https:\/\/www.judiciary.uk\/prevention-of-future-death-reports\/thomas-kingston-prevention-of-future-deaths-report\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2836262\/jamapsychiatry_kalfas_2025_oi_250035_1755883028.21448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:00:57Z","timestamp":1756911657000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2836262"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1362","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}